Skip to main content
Signal8
Launch Terminal

INSMED Inc (INSM)

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Insmed Incorporated logo

Insmed Incorporated

NASDAQ:INSMHealthcare
+0.89%$112.58
AH$112.01-0.51%vs close
Mkt Cap$24.7B
Float214.32M
O/S219.38M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Insmed Incorporated logoNASDAQ:INSM$112.58+0.89%
Upcoming Catalysts
Phase Distribution
50 lead-sponsored trials·6 active·36 completed
Phase 117
Phase 1/23
Phase 213
Phase 2/33
Phase 312
Not applicable2
(4 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

    Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer., Tobramycin inhalation solution using a PARI LC® Plus nebulizer.

    Pseudomonas Aeruginosa Infection

    Enrollment
    302
    Start
    Feb 2012
    Primary Completion
    Jun 2013
    Completion
    Sep 2013
    NCT01315678
  • Phase 3
    Withdrawn

    Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa

    Liposomal amikacin for inhalation, Placebo for liposomal amikacin for inhalation

    Cystic Fibrosis

    Enrollment
    0
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT01315691
  • Phase 3
    Completed

    Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

    Liposomal amikacin for inhalation

    Cystic Fibrosis

    Enrollment
    206
    Start
    Oct 2012
    Primary Completion
    Jul 2015
    Completion
    Jul 2015
    NCT01316276
  • Phase 3
    Completed

    Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

    LAI (Liposomal Amikacin for Inhalation) 590 mg

    Mycobacterium Infections, Nontuberculous

    Enrollment
    336
    Start
    May 2015
    Primary Completion
    Jul 2018
    Completion
    Apr 2019
    NCT02344004
  • Phase 3
    Completed

    Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

    LAI 590 mg, Multi-drug regimen

    NTM Lung Infection Due to MAC

    Enrollment
    163
    Start
    Feb 2016
    Primary Completion
    Oct 2018
    Completion
    Oct 2018
    NCT02628600
  • Phase 3
    Completed

    A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

    Brensocatib 10 mg, Brensocatib 25 mg

    Non-Cystic Fibrosis Bronchiectasis

    Enrollment
    1,767
    Start
    Dec 2020
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT04594369
  • Phase 3
    Completed

    Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

    ALIS, Azithromycin

    Mycobacterium Infections, Nontuberculous

    Enrollment
    99
    Start
    Dec 2020
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04677543
  • Phase 3
    Completed

    Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

    ALIS, Azithromycin

    Mycobacterium Infections, Nontuberculous

    Enrollment
    425
    Start
    Apr 2021
    Primary Completion
    Nov 2025
    Completion
    Jan 2026
    NCT04677569
  • Phase 3
    Recruiting

    Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Treprostinil Palmitil Inhalation Powder, Placebo

    Pulmonary Hypertension, Interstitial Lung Disease

    Enrollment
    344
    Start
    Jan 2026
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT07179380
  • Phase 3
    Recruiting

    An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Treprostinil Palmitil Inhalation Powder, Placebo

    Pulmonary Hypertension, Interstitial Lung Disease

    Enrollment
    344
    Start
    Jul 2026
    Primary Completion
    Jan 2031est.
    Completion
    Jan 2031est.
    NCT07234032
  • Phase 3
    Recruiting

    A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

    Treprostinil Palmitil Inhalation Powder, Placebo

    Pulmonary Arterial Hypertension

    Enrollment
    344
    Start
    Jul 2026
    Primary Completion
    Dec 2028est.
    Completion
    Jan 2029est.
    NCT07481981
  • Phase 3
    Not yet recruiting

    A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)

    Treprostinil Palmitil Inhalation Powder, Placebo

    Progressive Pulmonary Fibrosis, Interstitial Lung Disease

    Enrollment
    800
    Start
    Dec 2026est.
    Primary Completion
    Aug 2030est.
    Completion
    Aug 2030est.
    NCT07805785
  • Phase 2/3
    Completed

    IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

    rhIGF-I/rhIGFBP-3

    Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT00368173
  • Phase 2/3
    Completed

    An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

    Treprostinil Palmitil Inhalation Powder, Placebo

    Pulmonary Hypertension, Interstitial Lung Disease

    Enrollment
    31
    Start
    May 2023
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT05649722
  • Phase 2/3
    Active, not recruiting

    An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

    Treprostinil Palmitil, Placebo

    Pulmonary Arterial Hypertension

    Enrollment
    91
    Start
    Mar 2023
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT05649748
  • Phase 2
    Terminated

    Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

    rhIGF-1/rhIGFBP-3

    Noonan Syndrome

    Enrollment
    24
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT00351221
  • Phase 2
    Completed

    Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

    rhIGF-I/rhIGFBP-3, placebo

    Myotonic Dystrophy Type 1

    Enrollment
    69
    Start
    Dec 2007
    Primary Completion
    Dec 2008
    Completion
    Dec 2008
    NCT00577577
  • Phase 2
    Completed

    Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

    280 mg Arikayce™, Matching Placebo for Cohort 1

    Bronchiectasis

    Enrollment
    64
    Start
    Jun 2008
    Primary Completion
    May 2009
    Completion
    May 2009
    NCT00775138
  • Phase 2
    Completed

    Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

    Liposomal amikacin for inhalation (LAI), placebo

    Mycobacterium Infections, Nontuberculous

    Enrollment
    90
    Start
    Apr 2012
    Primary Completion
    Aug 2014
    Completion
    Jun 2015
    NCT01315236
  • Phase 2
    Completed

    Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

    Brensocatib 10 mg, Brensocatib 25 mg

    Non-Cystic Fibrosis Bronchiectasis

    Enrollment
    256
    Start
    Oct 2017
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03218917
  • Phase 2
    Completed

    Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

    Arikayce™

    Cystic Fibrosis

    Enrollment
    49
    Start
    Jan 2009
    Primary Completion
    Nov 2010
    Completion
    Nov 2010
    NCT03905642
  • Phase 2
    Terminated

    A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

    Treprostinil Palmitil

    Pulmonary Arterial Hypertension

    Enrollment
    1
    Start
    Mar 2022
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT04791514
  • Phase 2
    Completed

    A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

    Brensocatib, Placebo

    Cystic Fibrosis

    Enrollment
    29
    Start
    Nov 2021
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT05090904
  • Phase 2
    Completed

    A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

    Treprostinil Palmitil, Placebo

    Pulmonary Arterial Hypertension

    Enrollment
    102
    Start
    Aug 2022
    Primary Completion
    Mar 2025
    Completion
    Mar 2025
    NCT05147805
  • Phase 2
    Completed

    A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

    Treprostinil Palmitil, Placebo

    Pulmonary Hypertension

    Enrollment
    39
    Start
    Dec 2022
    Primary Completion
    Mar 2024
    Completion
    Mar 2024
    NCT05176951

1-25 of 50

Search ClinicalTrials.gov for “Insmed”